Oncology

Cancer steals possibility. We’re taking it back.

Gilead and Kite Oncology are working to transform how cancer is treated. We’re innovating with next-generation therapies, combinations and technologies to deliver improved outcomes for people with cancer. Our bold approach is redefining cancer research by accelerating development of therapies and potential cures.

IMPACT TO DATE

6

Approved indications in certain types of breast and blood cancers with high unmet need

11

Ongoing Phase 3 trials across 8 tumor types and stages of disease

~40

Collaborations providing access to industry-leading innovations in oncology

Cancer steals possibility. We're taking it back.™

Killing cancer cells from within

We develop therapies that selectively target and kill cancer cells with minimal impact on healthy tissue.

Engaging the immune system to fight cancer

We advance innovative approaches, like small molecules, therapeutic antibodies and cell therapies, that reprogram and stimulate the body’s own immune cells to recognize and eliminate cancer cells.

Disrupting the tumor microenvironment that enables cancer to grow

We develop therapies that disrupt the support network of cancer cells, allowing the body’s immune system and anti-cancer agents to work more effectively.

Our Pipeline of Transformative Advances

We’re purposefully building our oncology portfolio and pipeline to address the greatest gaps in care. From antibody-drug conjugate technologies and small molecules to cell therapy-based approaches, we're relentlessly committed to creating transformative therapies for people with cancer.

Explore Our Pipeline

The Promise of Cell Therapy at Kite

Kite, a Gilead Company, is singularly focused on achieving cures with cell therapy. We’re dedicated to the research, development, manufacturing and commercialization of cell therapy.

Learn More About Kite

Clinical Trials

We're committed to involving the communities most impacted by disease in the design and execution of our clinical trials.

Learn More

Medicines

We have developed more than 25 life-changing medicines to treat, prevent and transform conditions that impact millions of people and are rapidly growing our portfolio through research, development and external collaborations.

Learn More

Partnering for
Progress

We're transforming how cancer is treated by collaborating with partners from across the entire oncology community, including advocates, patients, industry and academia.

Partnerships play a key role in our growing pipeline and capabilities. Through approximately 40 active alliances and collaborations, we’re joining forces with some of the most promising oncology companies to access external sources of innovation, pursue next-generation cancer therapies and expand potential indications in our pipeline.

We actively partner with organizations across the cancer continuum to support the development and amplification of education and resources, advance equitable access and address care disparities.

Learn More About Our Corporate Giving Programs

Stories@Gilead

Follow our journey to create a healthier world for all people

View Stories@Gilead

Latest News

Some of the content on this page is not intended for users outside the U.S.

View News

Videos

U.S Military Veteran Battles Lymphoma with CAR T-cell Therapy: Marcus’s Story

U.S. Air Force veteran, Marcus, was home between deployments when he faced a personal battle with lymphoma. After six rounds of chemo, remission and a relapse, he joined a CAR T-cell Therapy trial that’s bringing him hope for tomorrow.
Gilead Pays Tribute to Patient Advocacy Work: Cara's Story
Toward Health Equity for Black People Impacted by TNBC: Update from Gilead Oncology Grantees

Toward Health Equity for Black People Impacted by triple-negative breast cancer (TNBC) is Gilead’s inaugural oncology grant program. In 2021-2022, the first cohort of grantees received funding for this program – a total of $5.7 million to 21 organizations. Many grantees are community-based groups focused on grassroots efforts, and others are advancing equity at the regional and national levels.